Struma ovarii presenting with Hashimoto's thyroiditis: a case report

Abstract Introduction We report the case of a patient diagnosed with a struma ovarii with lymphocytic thyroiditis of her ectopic thyroid tissue. We believe that this case presents an unusual variation of a struma ovarii and a rare presentation of subclinical hyperthyroidism. Case presentation A 17-year-old Caucasian female patient who had undergone an ovariectomy and been diagnosed with a struma ovarii was subsequently found to have persistent subclinical hyperthyroidism with a low radioiodine uptake. Abdominal magnetic resonance imaging and iodine-131 whole body scanning showed no residue or recurrence and a thyroid ultrasonography was normal. Laboratory and histopathological findings suggested Hashimoto's thyroiditis as the cause of the subclinical thyrotoxicosis, which had presumably started at the ectopic tissue. Conclusion Struma ovarii is a rare cause of thyrotoxicosis, and can be difficult to diagnose in the presence of co-existing thyroid disorders. In patients with a struma ovarii who have not undergone thyroidectomy, there is no common consensus on management in terms of residue, recurrence or metastasis. Autoimmune thyroiditis must be kept in mind for a differential diagnosis.</p

A case of hyperprolactinemia, probably induced by eletriptan

A 25-year-old woman with a severe migraine begins to use a migraine specific agent, eletriptan (40 mg/d). One month later, she had oligomenorrhea and galactorrhea. We ruled out all causes of hyperprolactinemia. To our knowledge, this is the first published postmarketing case report of eletriptan-induced hyperprolactinemia, presented as oligomenorrhea and galactorrhea in a patient. The Naranjo probability scale indicates a probable relationship between hyperprolactinemia and eletriptan therapy. ©2012 Dustri-Verlag Dr. K. Feistle

Stężenie białka S100B w surowicy jako przydatny wskaźnik w zespole obturacyjnego bezdechu podczas snu

Background and purpose We aimed to underline the importance of serum S100B protein as a useful biochemical marker in patients with obstructive sleep apnea syndrome (OSAS). Material and methods Forty-three newly diagnosed patients with OSAS (median apnea-hypopnea index [AHI, events/hour]: 37.5 [range 11.3–137]) and 25 subjects with AHI &lt; 5 (median AHI: 4.4 [range 0.7–4.8]) were included in the study. Serum S100B protein level was tested in serum samples taken after polysomnography in both groups and the difference between OSAS patients and the control group regarding that level was assessed. In addition, the association of S100B protein serum level with age, body mass index, AHI, mean O2 saturation percentage during sleep, minimum O2 saturation value (%) at the end of the apneas, and the time spent at an O2 saturation less than 90% were analyzed in the OSAS patient group. Results Median serum S100B protein level was 133.7 pg/mL (range 20.97–230.70 pg/mL) in patients with OSAS and 16.1 pg/mL (range 10.1–22.9 pg/mL) in the control group (p &lt; 0.005). Serum S100B protein level did not correlate with any studied variable (p &gt; 0.05 for each correlation coefficient). Conclusions Serum S100B protein level is increased in patients with OSAS and may be a useful biochemical marker in those patients.Wstęp i cel pracy Celem pracy było podkreślenie znaczenia stężenia białka S100B w surowicy jako przydatnego wskaźnika biochemicznego u chorych na zespół obturacyjnego bezdechu podczas snu (obstructive sleep apnea syndrome – OSAS). Materiał i metody W badaniu wzięło udział 43 chorych ze świeżo rozpoznanym OSAS [mediana wskaźnika bezdechów/spłyconych oddechów, AHI (epizody na godzinę): 37,5 (zakres: 11,3–137)] oraz 25 osób z AHI &lt; 5 [mediana: 4,4 (0,7–4,8)] stanowiących grupę kontrolną. W obu grupach zmierzono stężenie białka S100B w surowicy pobranej po wykonaniu polisomnografii i sprawdzono różnicę w tym zakresie między grupami. Ponadto w grupie chorych na OSAS określono korelację między stężeniem białka S100B w surowicy a wiekiem, wskaźnikiem masy ciała, AHI, średnim wysyceniem krwi tętniczej tlenem podczas snu, najmniejszym wysyceniem krwi tętniczej tlenem na zakończenie okresu bezdechu oraz czasem, w którym wysycenie krwi tętniczej tlenem wynosiło &lt; 90%. Wyniki Mediana stężenia białka S100B w surowicy wyniosła 133,7 pg/ml (zakres: 20,97–230,70 pg/ml) u chorych na OSAS oraz 16,1 pg/ml (zakres: 10,1–22,9 pg/ml) w grupie kontrolnej (p &lt; 0,005). Stężenie białka S100B w surowicy nie korelowało z żadną ocenianą zmienną (p&gt; 0,05 dla każdego współczynnika korelacji). Wnioski Stężenie białka S100B w surowicy jest zwiększone u chorych na OSAS i może być przydatnym wskaźnikiem biochemicznym u tych pacjentów